Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics
Source: SeekingAlpha
2026-03-11 06:00:21 ET
More on CRISPR Therapeutics
- Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
- Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward
- CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
- CRISPR Therapeutics stock dips on $350M convertible debt offering
- Key deals this week: KORE, TopBuild, Equinix, PayPal and more
Read the full article on Seeking Alpha
For further details see:
Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics
Teradyne Inc.
NASDAQ: TER
TER Trading
-1.36% G/L:
$287.94 Last:
724,837 Volume:
$290 Open:
TER Latest News
March 03, 2026 03:00:00 am
LitePoint, Aethertek, and Metanoia Announce Joint Collaboration to Create High Bandwidth Technology for Dense Environments
February 23, 2026 09:00:00 pm
Teradyne to Showcase Leading Semiconductor Test Solutions at IESA Vision Summit
TER Stock Data
$47,986,350,122
155,042,220
0.02%
499
N/A
Semiconductors and Equipment
Technology
US
North Reading
